Literature DB >> 7541823

Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development.

M Miyazawa1, R Fujisawa, C Ishihara, Y A Takei, T Shimizu, H Uenishi, H Yamagishi, K Kuribayashi.   

Abstract

Synthetic peptide vaccines containing a single Th cell epitope identified in the gp70 envelope glycoprotein of Friend murine leukemia helper virus induced potent protective immunity against Friend virus infection. H-2a/b mice immunized by a single s.c. injection of the CFA emulsion containing a peptide that represented the N-terminal gp70 epitope recovered slowly from initial development of splenomegaly, and most did not develop late leukemia, whereas most of the control mice given an injection of CFA alone showed sustained leukemic splenomegaly after the challenge with Friend virus. The mice of the same genetic background immunized with the C-terminal Th cell epitope by a single injection of a separate synthetic peptide eliminated virus-producing cells from the spleen within 12 days after inoculation of Friend virus complex, and did not develop early splenomegaly or polycythemia. H-2a/a mice were not protected by immunization with either one of the two synthetic peptides. Earlier production and more rapid class switching of virus-neutralizing Abs were observed in H-2a/b mice immunized with the peptide vaccines after the challenge with Friend virus, compared with the responses of the control mice. Detailed kinetic and immunohistopathologic analyses suggested that Th cells might be directly involved in the growth inhibition and elimination of virus-infected erythroid precursor cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541823

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Elimination of friend retrovirus in the absence of CD8+ T cells.

Authors:  Sachiyo Tsuji-Kawahara; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

Review 2.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Role of natural killer cells in resistance against friend retrovirus-induced leukemia.

Authors:  N Iwanami; A Niwa; Y Yasutomi; N Tabata; M Miyazawa
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Differing T-cell requirements for recombinant retrovirus vaccines.

Authors:  K J Hasenkrug; D M Brooks; J Nishio; B Chesebro
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Natural killer cells recognize friend retrovirus-infected erythroid progenitor cells through NKG2D-RAE-1 interactions In Vivo.

Authors:  Tatsuya Ogawa; Sachiyo Tsuji-Kawahara; Takae Yuasa; Saori Kinoshita; Tomomi Chikaishi; Shiki Takamura; Haruo Matsumura; Tsukasa Seya; Toshihiko Saga; Masaaki Miyazawa
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

6.  Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected mice.

Authors:  Sachiyo Tsuji-Kawahara; Tomomi Chikaishi; Eri Takeda; Maiko Kato; Saori Kinoshita; Eiji Kajiwara; Shiki Takamura; Masaaki Miyazawa
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

7.  Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice.

Authors:  K J Hasenkrug
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection.

Authors:  Rebecca Pike; Andrew Filby; Mickaël J-Y Ploquin; Urszula Eksmond; Rute Marques; Inês Antunes; Kim Hasenkrug; George Kassiotis
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

9.  Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for regulation of retrovirus-induced myeloid leukemia development.

Authors:  Sachiyo Tsuji-Kawahara; Hiroyuki Kawabata; Hideaki Matsukuma; Saori Kinoshita; Tomomi Chikaishi; Mayumi Sakamoto; Yuri Kawasaki; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

10.  Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.

Authors:  U Dittmer; D M Brooks; K J Hasenkrug
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.